<SEC-DOCUMENT>0001104659-25-081941.txt : 20250822
<SEC-HEADER>0001104659-25-081941.hdr.sgml : 20250822
<ACCEPTANCE-DATETIME>20250822170031
ACCESSION NUMBER:		0001104659-25-081941
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250822
DATE AS OF CHANGE:		20250822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ClearSign Technologies Corp
		CENTRAL INDEX KEY:			0001434524
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289549
		FILM NUMBER:		251247040

	BUSINESS ADDRESS:	
		STREET 1:		8023 E. 63RD PLACE, SUITE 101
		CITY:			TULSA
		STATE:			OK
		ZIP:			74133
		BUSINESS PHONE:		(918) 236-6461

	MAIL ADDRESS:	
		STREET 1:		8023 E. 63RD PLACE, SUITE 101
		CITY:			TULSA
		STATE:			OK
		ZIP:			74133

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLEARSIGN COMBUSTION CORP
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>tm2523685d3_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule&nbsp;424(b)(4)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-289549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="tm2523685d3_424b4img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,267,222 Shares of Common Stock Underlying
the Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the issuance of up to 5,267,222 shares of our common stock, par value $0.0001 per share, or the common stock, available for issuance upon
the exercise of 5,267,222 redeemable warrants, or the Warrants, previously issued as part of our public offering of shares of common stock
and accompanying Warrants, at the rate of one Warrants for every one share of common stock, that was completed on April&nbsp;23, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Warrant has an initial
exercise price of $1.05 per share, subject to adjustments, and may only be exercised in cash at the election of the holder at any time
beginning on April&nbsp;23, 2024, the date of issuance, and from time to time thereafter, through and including the fifth anniversary
of the issuance date. The Warrants are redeemable by us from time to time, subject to certain market based criteria. Holders of the Warrants
are not able to exercise their Warrants on a cashless basis. See &ldquo;Description of Securities Being Registered&rdquo; in this prospectus
for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may receive up to $5.5
million upon the exercise of the Warrants, if and when the warrant holders elect to exercise such Warrants. We will not receive any proceeds
from the sale of the underlying common stock by the holders of the Warrants. Any amounts received from such exercises will be used for
working capital, research and development, marketing and sales, and general corporate purposes. All costs and expenses incurred in connection
with the registration of the offering made hereby will be paid by us. The registration of these shares of common stock does not necessarily
mean that any holder of a Warrant will exercise such Warrant or that the underlying shares of common stock will be offered or sold by
such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on the Nasdaq Capital Market, or Nasdaq, under the symbol &ldquo;CLIR&rdquo;. On August 20, 2025, the last reported sale price of our
common stock on Nasdaq was $0.552.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus,
together with additional information described under the headings &ldquo;Information Incorporated by Reference&rdquo; and &ldquo;Where
You Can Find More Information,&rdquo; carefully before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves a high
degree of risk. See &ldquo;<A HREF="#a_006">Risk Factors</A>&rdquo; beginning on page&nbsp;9 of this prospectus and other filings we make with the Securities
and Exchange Commission from time to time, which are incorporated by reference herein in their entirety, together with other information
in this prospectus and the information incorporated by reference herein.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is August 21, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 90%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#a_001">3</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Market,&nbsp;Industry and Other Data</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Disclosure Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">4</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">5</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">9</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">8</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">9</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Determination of Offering Price</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">10</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">11</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Description of Securities Being Offered</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">11</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">12</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">13</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">13</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Information Incorporated by Reference</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">14</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">14</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus provides you
with a general description of the shares of common stock issuable upon exercise of the Warrants offered by us. In certain circumstances,
we may provide a prospectus supplement that will contain specific information about the terms of a particular offering. We also may provide
a prospectus supplement to add information to, or update or change information contained in, this prospectus. To the extent there is a
conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in the
prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having
a later date&thinsp;&mdash;&thinsp;for example, a document incorporated by reference in this prospectus or any prospectus supplement&thinsp;&mdash;&thinsp;the
statement in the later-dated document modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read both this
prospectus and any applicable prospectus supplement together with the additional information about our company to which we refer you in
the sections of this prospectus titled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Information Incorporated by Reference.&rdquo;
You should rely only on the information contained in or incorporated by reference into this prospectus and any prospectus supplement.
We have not authorized any dealer, salesperson or other person to provide you with different information. You should not assume that the
information in this prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents
or that any document incorporated by reference is accurate as of any date other than its filing date. You should not consider this prospectus
to be an offer or solicitation relating to the shares of common stock issuable upon exercise of the Warrants in any jurisdiction in which
such an offer or solicitation relating to such shares of common stock is not authorized. Furthermore, you should not consider this prospectus
to be an offer or solicitation relating to the shares of common stock issuable upon exercise of the Warrants if the person making the
offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is an offer
to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. This prospectus
is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is
not permitted. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to
the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the
section titled &ldquo;Where You Can Find Additional Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
otherwise stated or the context otherwise requires, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;ClearSign&rdquo;
and the &ldquo;Company&rdquo; refer to ClearSign Technologies Corporation and its subsidiary, ClearSign Asia Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>MARKET,&nbsp;INDUSTRY AND OTHER DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, including
the information incorporated by reference, contains estimates, projections and other information concerning our industry, our business
and the markets for certain products and services, including data regarding the estimated size of those markets and their projected growth
rates. Information that is based on estimates, forecasts, projections or similar methodologies is based on a number of assumptions and
is inherently subject to uncertainties, including those described in &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus, and
documents we incorporate by reference, and actual events or circumstances may differ materially from events and circumstances reflected
in this information. You are cautioned not to give undue weight to such estimates, projections and other information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, including
the documents that we incorporate by reference, may contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities
Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
in this prospectus include, without limitation, statements related to our plans, strategies, objectives, expectations, intentions and
adequacy of resources. Investors are cautioned that such forward-looking statements involve risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Factors that could cause actual
results to differ from those discussed in the forward-looking statements include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
limited cash, history of losses, and our expectation that we will continue to experience operating losses and negative cash flows in the
near future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
ability to successfully develop and implement our technologies and achieve profitability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
limited operating history;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
ability to maintain the listing of our common stock on Nasdaq;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;changes
in government regulations that could substantially reduce, or even eliminate, the need for our technology;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;emerging
competition and rapidly advancing technology in our industry that may outpace our technology;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;customer
demand for the products and services we develop;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
impact of competitive or alternative products, technologies, and pricing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
ability to manufacture any products we design;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;general
economic conditions and events and the impact they may have on us and our potential customers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
impact of global supply-chain constraints and the threat of, or implementation of, tariffs on imported or exported goods and materials
may adversely affect our commercialization efforts and business operations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
revenue has been highly concentrated among a small number or customers, and our results of operations could be harmed if we lose a key
revenue source and fail to replace it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
impact of a cybersecurity incident or other technology disruption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
ability to protect our intellectual property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
our ability to obtain adequate financing in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
ability to retain and hire personnel with the experience and talent to develop our products and business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;our
success at managing the risks involved in the foregoing items; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
factors discussed in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, you can identify
forward-looking statements by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;plans,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo;
 &ldquo;potential,&rdquo; or &ldquo;continue&rdquo; or the negative of such terms or other comparable terminology. Although we believe
that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. We do not undertake any obligation to publicly update or review any forward-looking statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.125in; padding-left: 0.125in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained elsewhere or incorporated by reference in this prospectus and in the documents we incorporate by reference. This
summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should read
this entire prospectus carefully, including the &ldquo;Risk Factors&rdquo; section contained in this prospectus and in the documents we
incorporate by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
design and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial
combustion systems, including emission and operational performance, energy efficiency, and overall cost-effectiveness. We believe that
our patented ClearSign Core&trade; technology can enhance the performance of combustion systems in a broad range of markets, including
the energy (upstream oil production, midstream gas processing and transportation, and down-stream refining), institutional, commercial
and industrial boiler, chemical, and petrochemical industries. Our ClearSign Core<SUP>TM</SUP>&nbsp;technology, which is our primary technology,
uses either a porous ceramic structure or metal flame holder device held at a distance from the injection planes of a burner to significantly
reduce flame length and achieve low emissions without the need for external flue gas recirculation, selective catalytic reduction, or
high excess air systems. To date, our operations have been funded primarily through sales of our equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
combustion technology has been successfully deployed in commercial projects such as down-stream refining and upstream oil production.
These applications include our process burner, flaring and boiler burner technologies. Both our process burner and boiler burner technology
can operate in high-intensity industrial burner applications at sites that are required to meet low air pollutant emissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe that combustion equipment utilizing ClearSign Core<SUP>TM</SUP>&nbsp;technology is more effective and cost-efficient than current
industry-standard air pollution control technologies and can reduce nitrogen oxide (&ldquo;NOx&rdquo;) emissions down to the levels required
by new stringent emission regulations. NOx is a regulated greenhouse gas pollutant comprised of nitrogen oxide and nitrogen dioxide. These
current industry-standard air pollution control technologies include selective catalytic reduction devices (&ldquo;SCRs&rdquo;), low-
and ultra-low NOx burners, external flue gas recirculation systems and other similar technologies. Such air pollution control systems
are widely used in places within our current target markets such as petroleum refining and petrochemical process heaters, large-scale
once through steam generators (&ldquo;OTSGs&rdquo;), enclosed flares, institutional commercial and industrial boilers and other similar
equipment. We believe that our ClearSign Core<SUP>TM</SUP>&nbsp;technology can provide value to our customers not only by helping them
meet current and possible future legislative mandates to reduce pollutant emissions, but also by improving operating efficiency and increasing
overall return on investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
on the operating data we have obtained from our installed products, burners utilizing ClearSign Core<SUP>TM</SUP>&nbsp;technology can
provide increased heat transfer efficiency as compared to other emission reducing technologies. This is consistent with the physics of
heat transfer and the mechanisms by which the technology functions. The reported increased heat transfer efficiency may potentially result
in cost savings in the low to mid-single digit percentage range for burners employing our technology. We believe that these potential
costs savings could produce a significantly attractive pay-back period for an investment in ClearSign Core<SUP>TM</SUP>&nbsp;technology-based
burners. In addition, because the flame volumes in heaters utilizing ClearSign Core<SUP>TM</SUP>&nbsp;technology are typically small,
heaters using our technology are expected to operate at a lower cost, have increased productivity, and require less maintenance and downtime
compared to heaters that operate with enlarged flames produced by traditional low NOx burners. The flames in a ClearSign Core<SUP>TM</SUP>&nbsp;system
are established from a predominantly premixed stream of fuel, combustion air and flue gasses stabilized on a downstream structure that
promotes turbulence and ignition with minimal &ldquo;bulking up.&rdquo; In comparison, flames resulting from the traditional legacy process
of slow mixing of the fuel and air, and dilutive inert flue gasses have a much larger size. With a lower volume flame in a ClearSign Core<SUP>TM</SUP>&nbsp;system,
surfaces in the heater or boiler experience less touching by the flame and it is anticipated that our systems can virtually eliminate
flame impingement. Our technology also enables burners to function better in tightly spaced heaters compared to the flames of traditional
low NOx burners. Most importantly, using our technology has the potential to decrease process downtime required during installation compared
to retrofits utilizing the legacy technology of SCRs or flue gas recirculation systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are also designing and commercializing a range of sensing products called the ClearSign Eye for two potential markets. The primary addressable
market is similar to that of our ClearSign Core<SUP>TM</SUP>&nbsp;technology, although not limited to regions requiring emissions reduction.
The flame sensing products are applicable to all installed burners that use a pilot for ignition, including in markets and regions beyond
those where reducing emissions is a high priority. Like our burner technology, our burner sensing technology is being developed to provide
convenient replacement and retrofit solutions for existing equipment as well as for inclusion in newly built equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
secondary potential market for our sensing technology is outside of the typical combustion industry and includes transportation industries.
We are collaborating with Narion Corporation to further develop our technology for this industry, which allows us to incur minimal costs
while pursuing this market opportunity. While use of this fundamental technology in applications intended for transportation markets is
proven, the development and refinement of specific products, obtaining the certifications required for commercial deployment and establishing
an efficient manufacturing source and channels to market will take some time, and we cannot assure that these goals will be achieved.
We believe that the opportunities for application of our sensing technology in the transportation market are global and of great value,
but it will also take longer to commercialize products targeted for this market for the reasons stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Overall,
our sensing technologies could provide future diversification as well as the opportunity for continued business expansion and growth beyond
the maturation of our combustion-related businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.125in; padding-left: 0.125in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
combustion and emissions control systems markets are significant, both with respect to the wide array of industries in which the systems
are used and the amount of capital spent installing and upgrading the systems. Combustion systems are used to provide heat for many different
industrial and commercial processes, including boilers, petrochemical process heaters, and waste disposal systems. In order to maximize
energy efficiency while keeping pace with regulatory guidelines for air pollution emissions, operators of combustion systems are continually
installing, maintaining, and upgrading a variety of costly process control, air pollution control and monitoring systems. Although we
believe that there are many potential markets for our ClearSign Core&trade; technology, to date we have limited the introduction of this
technology to petroleum refining process heaters, energy infrastructure process heaters, boilers for steam and hot water generation, boilers
for building heating systems, and enclosed flares. We have initially targeted these markets for various reasons, such as, but not limited
to: (i)&nbsp;environmental regulations imposed on these markets, (ii)&nbsp;total available market size, (iii)&nbsp;this technology being
the most readily adapted to the needs of these industries and (iv)&nbsp;management experience and expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
initial target markets center on the energy sector, including downstream oil refineries through the use of process heaters and boilers
as well as upstream crude oil production through the use of OTSGs and wellhead enclosed flares. We believe operators in our domestic target
markets are under pressure to meet current and proposed federal, state and local pollution emissions standards. The standards applicable
to our target markets have been developed over the past 50 years with broad political input. Due to the localized effects of poor air
quality, we expect these standards to continue to become more stringent regardless of political leadership. As an illustration, air pollution
emission standards are most stringent in the states of California and Texas, which historically have had leadership from different political
parties. We believe this to be the case in the U.S. and worldwide in most major developed and developing countries. As a result, these
standards are a significant driver for our development and sales efforts. We believe that our ClearSign Core<SUP>TM</SUP>&nbsp;technology
can provide a unique, cost-effective pollution control solution for operators in comparison to known competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Notice of Delisting
or Failure to Satisfy a Continued Listing Rule&nbsp;or Standard</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April&nbsp;1, 2025, we received a letter (the &ldquo;Notice&rdquo;) from Nasdaq&rsquo;s Listing Qualifications Staff (the &ldquo;Staff&rdquo;)
indicating that, based upon the closing bid price of our common stock for the 30 consecutive business days beginning on February&nbsp;18,
2025, and ending on March&nbsp;31, 2025, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth
in Nasdaq Listing Rule&nbsp;5550(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
accordance with Nasdaq Listing Rule&nbsp;5810(c)(3)(A), we have been provided a period of 180 calendar days, or until September&nbsp;29,
2025, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of our
common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180 day period. In the event that
we do not regain compliance within this 180 day period, we may be eligible to seek an additional compliance period of 180 calendar days
if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq,
with the exception of the bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this
second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that we will not be able
to cure the deficiency, or if we are not otherwise eligible, Nasdaq will provide notice to us that our common stock will be subject to
delisting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Notice does not result in the immediate delisting of our common stock from Nasdaq. We intend to monitor the closing bid price of our common
stock and consider its available options in the event that the closing bid price of our common stock remains below $1 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>ATM Program Termination</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Effective
as of July&nbsp;12, 2025, we terminated our At-the-Market Sales Agreement, dated as of December&nbsp;23, 2020 (the &ldquo;Virtu Sales
Agreement&rdquo;), with Virtu Americas LLC. At the time of termination, we had sold 1,594,285 shares of our common stock under the Virtu
Sales Agreement for aggregate gross proceeds of approximately $6,122,650.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Wainwright ATM
Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
July&nbsp;17, 2025, we entered into&nbsp;<FONT STYLE="background-color: white">an At The Market Offering Agreement (the &ldquo;ATM Agreement&rdquo;)
with H.C. Wainwright&nbsp;&amp; Co., LLC (&ldquo;Wainwright&rdquo;). In accordance with the terms of the ATM Agreement, we may offer and
sell from time to time through Wainwright, acting as sales agent, shares of our common stock having an aggregate offering price of up
to $10,390,000 (the &ldquo;Placement Shares&rdquo;). The Placement Shares will be issued pursuant to the Company&rsquo;s shelf registration
statement on Form&nbsp;S-3&nbsp;</FONT>filed with the SEC on July&nbsp;17, 2025 (the &ldquo;Registration Statement&rdquo;) and the prospectus
relating to the offer and sale of the Placement Shares that forms a part of the Registration Statement, which was declared effective by
the SEC on July&nbsp;28, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Second Notice of
Delisting or Failure to Satisfy a Continued Listing Rule&nbsp;or Standard</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August&nbsp;8, 2025, we received a notice (the &ldquo;Second Notice&rdquo;) from Nasdaq&rsquo;s Listing Qualifications Department stating
that we are not in compliance with the board of directors independence requirement set forth in Nasdaq Listing Rule&nbsp;5605(b)(1)&nbsp;and
the audit committee composition requirement set forth in Nasdaq Listing Rule&nbsp;5605(c)(2)(A)&nbsp;(collectively, the &ldquo;Nasdaq
Composition Requirements&rdquo;) due to the resignations of Catharine M. de Lacy and Judith S. Schrecker from the Company&rsquo;s board
of directors (the &ldquo;board of directors&rdquo;) on August&nbsp;4, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.125in; padding-left: 0.125in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Specifically,
when the Second Notice was issued, the board of directors did not have a majority of directors that would be considered &ldquo;independent
directors,&rdquo; as that term is defined in Nasdaq Listing Rule&nbsp;5605(a)(2), and the Audit and Risk Committee of the board of directors
(the &ldquo;Audit Committee&rdquo;) consisted of only two independent directors, rather than the minimum three independent directors as
required by Nasdaq Listing Rule&nbsp;5605(c)(2)(A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
intend to regain compliance with the Nasdaq Composition Requirements by appointing a new director to the board of directors and Audit
Committee who meets the independence requirements under Nasdaq rules&nbsp;and Rule&nbsp;10A-3(b)(1)&nbsp;under the Exchange Act. Consistent
with Nasdaq Listing Rules&nbsp;5605(b)(1)(A)&nbsp;and 5605(c)(4), Nasdaq has provided us a cure period in order to regain compliance with
the Nasdaq Composition Requirements (i)&nbsp;until the earlier of our next annual meeting of stockholders or one year from the resignation
of Mss. de Lacy and Schrecker, or August&nbsp;4, 2026, or (ii)&nbsp;if our next annual meeting of stockholders is held before February&nbsp;2,
2026, then no later than February&nbsp;2, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Second Notice has no immediate effect on the listing of our common stock on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
were incorporated in the State of Washington on January&nbsp;23, 2008. Effective June&nbsp;14, 2023, we changed our domicile from the
State of Washington to the State of Delaware by means of a plan of conversion. The address of our corporate headquarters is 8023 East
63rd Place, Suite&nbsp;101, Tulsa, Oklahoma 74133 and our telephone number is (918) 236-6461. Our website can be accessed at www.clearsign.com.
We currently operate in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Information
contained in, or accessible through, our website does not constitute part of this prospectus or registration statement and inclusions
of our website address in this prospectus or registration statement are inactive textual references only. You should not rely on any such
information in making your decision whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are a &ldquo;smaller reporting company&rdquo; as defined under U.S. federal securities laws and are subject to reduced public company
reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 0.125in; padding-left: 0.125in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt"><B>Shares of common stock offered</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 63%; text-align: justify"><FONT STYLE="font-size: 10pt">We are offering 5,267,222 shares of common stock, which are issuable upon the exercise of our outstanding Warrants to purchase shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Shares of common stock to be outstanding immediately after this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">57,693,504 shares of common stock, assuming the exercise of the Warrants in full.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">We may receive up to $5.5 million upon the exercise of the Warrants, if and when the Warrant holders elect to exercise such Warrants. We will not receive any proceeds from the sale of the underlying common stock. Please see the section titled &ldquo;Plan of Distribution&rdquo; on page&nbsp;13 for more information regarding the distribution of the Warrants. Please refer to &ldquo;Description of Securities Being Registered,&rdquo; beginning on page&nbsp;12 for the description of the Warrants. We intend to use the net proceeds from any exercise of the Warrants for working capital, research and development, marketing and sales, and general corporate purposes. Please see the section entitled see &ldquo;Use of Proceeds&rdquo; on page&nbsp;10 of this prospectus for a more detailed discussion.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Market for our securities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our common stock is currently traded on Nasdaq under the symbol &ldquo;CLIR.&rdquo; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investment in our securities involves a high degree of risk. Please see the section entitled &ldquo;Risk Factors&rdquo; beginning on page&nbsp;9 of this prospectus and the risk factors incorporated by reference into this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of common
stock to be outstanding after this offering is based on 52,426,282 shares outstanding as of August 20, 2025, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Approximately 1,234,000
shares of common stock issuable upon the vesting of outstanding restricted stock units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Approximately
2,397,000 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $2.03 per share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Approximately
491,000 shares issuable upon the exercise of outstanding stock options granted outside of our Equity Incentive Plans (as defined below)
at a weighted average exercise price of $1.53 per share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Approximately
1,535,000 shares reserved for future issuances under the ClearSign Technologies Corporation 2021 Equity Incentive Plan (the &ldquo;2021
Plan&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Approximately
278,000 shares reserved for future issuances under the ClearSign Technologies Corporation 2013 Consultant Stock Plan (the &ldquo;Consultant
Plan,&rdquo; together with the ClearSign Technologies Corporation 2011 Equity Incentive Plan and the 2021 Plan, the &ldquo;Equity Incentive
Plans&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;425,109
shares of our common stock issuable upon exercise of underwriter warrants issued to Public Ventures, LLC (&ldquo;Public Ventures&rdquo;)
in connection with an underwritten public offering at an exercise price of $1.1375 per share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;15,147,606
shares of common stock issuable upon exercise of certain redeemable warrants outstanding at an exercise of $1.05 per share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;2,795,395
shares of common stock issuable upon exercise of certain pre-funded warrants outstanding at an exercise of $0.0001 per share; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;432,432
shares of common stock issuable upon exercise of placement agent warrants issued to Public Ventures as placement agent at an exercise
of $1.1375 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our securities
involves a high degree of risk. You should consider carefully the risks and uncertainties described below, and incorporated by reference
herein, together with all of the other information in, or incorporated by reference in, this prospectus, including our financial statements
and related notes incorporated by reference herein, before making an investment decision If any of these risks actually occurs, our business,
financial condition, results of operations or cash flow could suffer materially. In such an event, the trading price of our shares of
common stock could decline, and you might lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering and to Our Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the Warrant holders exercise their Warrants
in full and sell significant amounts of common stock, or the perception exists that these sales could occur, such events could cause the
common stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
issuable upon exercise of the Warrants being registered for resale in this prospectus will be freely tradable without restriction or further
registration under the&nbsp;Securities Act upon exercise of the Warrants. As a result, a substantial number of shares of common stock
may be sold in the public market to the extent the Warrants are exercised. If there are significantly more shares of common stock offered
for sale than buyers are willing to purchase, then the market price of the common stock may decline to a market price at which buyers
are willing to purchase the offered common stock and sellers remain willing to sell common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to utilize our common stock
to finance future capital needs, or for other purposes, is limited by the number of authorized shares of common stock currently available
for issuance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of the date of this prospectus, we had authority to issue a total of 87,500,000 shares of common stock, of which 52,426,282 shares of
common stock have been issued and approximately 30,000,000 shares of common stock are reserved for issuance in connection with certain
securities issued under our Equity Incentive Plans and other outstanding securities, including stock options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have historically financed our operations primarily through issuances of equity securities. With the limited shares of common stock presently
available for issuance, our ability to secure additional financing through the sale of common stock, to the extent needed, is limited.
Absent an increase in the shares of common stock authorized to be issued under our certificate of incorporation, we will be limited to
other financing structures in the event additional financing is required. Such alternative structures may be less favorable or unavailable
in which case we may be forced to forego opportunities or required to downsize operations due to lack of funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will have broad discretion as to the
proceeds that we receive from the exercise by any holder of the Warrants, and we may not use the proceeds effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will not receive any of the proceeds from the sale of the shares of common stock underlying the Warrants. However, we may receive up to
approximately $5.5 million in aggregate gross proceeds from the exercise of the Warrants, based on the per share exercise price of the
Warrants, and to the extent that we receive such proceeds, we intend to use the net proceeds from the exercise of the Warrants for working
capital, research and development, marketing and sales, and general corporate purposes. We have considerable discretion in the application
of such proceeds. You will not have the opportunity, as part of your investment decision, to assess whether such proceeds are being used
in a manner agreeable to you. You must rely on our judgment regarding the application of the net proceeds from the exercise of the Warrants,
which may be used for corporate purposes that do not improve our profitability or increase the price of our shares of common stock. Such
proceeds may also be placed in investments that do not produce income or that lose value. The failure to use such funds by us effectively
could have a material adverse effect on our business, financial condition, operating results and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience future dilution as a
result of issuance of the shares of common stock underlying the Warrants, future equity offerings by us and other issuances of our common
stock or other securities. In addition, the issuance of the shares of common stock upon exercise of the Warrants, to the extent the Warrants
are exercised, and future equity offerings and other issuances of our common stock or other securities may adversely affect our common
stock price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may experience future
dilution as a result of issuance of the shares of common stock underlying the Warrants, future equity offerings by us and other issuances
of our common stock or other securities. In order to raise additional capital, we may in the future offer additional shares of our common
stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share
as prior issuances of common stock. We may not be able to sell shares or other securities in any other offering at a price per share that
is equal to or greater than the price per share previously paid by investors, and investors purchasing shares or other securities in the
future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock
or securities convertible into common stock in future transactions may be higher or lower than the prices per share for previous issuances
of common stock or securities convertible into common stock paid by certain investors. In addition, the exercise price of the Warrants
may be equal to or greater than the price per share previously paid by certain investors. You will incur dilution upon exercise of any
outstanding stock options, warrants or upon the issuance of shares of common stock under our equity incentive programs. In addition, the
issuance of the shares of common stock underlying the Warrants and any future sales of a substantial number of shares of our common stock
in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict
the effect, if any, that market sales of those shares of common stock or the availability of those shares for sale will have on the market
price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>In making your investment decision, you should rely only on statements
made in this prospectus in determining whether to purchase our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully evaluate
all of the information in this prospectus. We have received in the past, and may continue in the future to receive, media coverage, including
coverage that is not directly attributable to statements made by our officers and employees, that incorrectly reports on statements made
by our officers or employees or that is misleading as a result of omitting to state information provided by us or our officers or employees.
You should rely only on the information contained in this prospectus in determining whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our common stock may be volatile,
and the market price of our common stock may decrease.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The price of our common stock
may vary from time to time. The factors that may cause the market price of our common stock to fluctuate include, but are not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">progress, or lack of progress, in developing and commercializing our technology;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to recruit and retain qualified personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in the perception of investors and securities analysts regarding the risks to our business or the condition of our business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in our relationships with key customers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in the market valuation or earnings of our competitors or companies viewed as similar to us;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in key personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">changes in our capital structure, such as future issuances of securities or the incurrence of debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the granting or exercise of employee stock options or other equity awards; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">general market and economic conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the equity markets
have experienced significant price and volume fluctuations that have affected the market prices for the securities of small companies
such as ours for a number of reasons, including reasons that may be unrelated to the business or operating performance. These broad market
fluctuations may result in a material decline in the market price of our common stock and you may not be able to sell your shares of common
stock at prices you deem acceptable. In the past, following periods of volatility in the equity markets, securities class action lawsuits
have been instituted against public companies. Such litigation, if instituted against us, could result in substantial cost and in the
diversion of management attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross proceeds that we
receive from the exercise of the Warrants will depend upon the number of Warrants exercised. If the Warrants are exercised in full, we
will receive gross proceeds of approximately $5.5 million. There can be no assurance that any Warrant holder will exercise Warrants, especially
since, as of the date of this prospectus, none of the Warrants are in-the-money.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
from the exercise of the Warrants for working capital, research and development, marketing and sales, and general corporate purposes.
We have broad discretion in determining how the proceeds from the exercise of the Warrants, if any, will be used, and our discretion is
not limited by the aforementioned possible uses. Our board of directors believes the flexibility in application of the net proceeds is
prudent. See the section entitled &ldquo;Risk Factors &ndash; Risks Related to this Offering and to our Common Stock &ndash; We will have
broad discretion as to the proceeds that we receive from the exercise by any holder of the Warrants, and we may not use the proceeds effectively.&rdquo;&nbsp;This
expected use of the net proceeds from any exercise of the Warrants represents our intentions based upon our current plans and business
conditions, and our management will retain broad discretion as to the ultimate allocation of the proceeds. We may temporarily invest funds
that we do not immediately need for these purposes in investment securities or use them to make payments on our borrowings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will bear all other costs,
fees and expenses incurred in effecting the registration of the offer and sale of the shares issuable upon exercise of the Warrants covered
by this prospectus and any accompanying prospectus supplement, including, without limitation, all registration and filing fees, Nasdaq
listing fees and fees and expenses of our counsel and our accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>DETERMINATION
OF OFFERING PRICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms and the public offering
prices of the securities offered in the underwritten public offering in which we issued the Warrants were determined by negotiations between
us and the underwriter. Among the factors considered in determining the public offering price were our future prospects and those of our
industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings
ratios, price-sales ratios, market prices of our securities and the securities of other public companies, market conditions, and certain
financial and operating information of companies engaged in activities similar to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>Dilution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Warrants are exercised
in full, your ownership interest will be diluted to the extent of the difference between the Warrants&rsquo; exercise price per share
and our pro forma net tangible book value per share immediately after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our historical net tangible
book value as of June 30, 2025, was approximately $9.6 million, or $0.18 per share of common stock. We calculate net tangible book value
per share by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of
June 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to the
exercise of all outstanding Warrants at an exercise price of $1.05 per share, and after deducting estimated aggregate offering expenses
payable by us, our pro forma net tangible book value as of June 30, 2025, is approximately $15.1 million. This represents an immediate
increase in net tangible book value of $0.08 per share of common stock to existing stockholders and an immediate dilution in net tangible
book value of $0.79 per share of common stock to the holders of the outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table illustrates
this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt">Exercise price per share</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.05</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Net tangible book value per share as of June 30, 2025</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.18</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Increase in net tangible book value per share attributable to this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.08</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Pro forma net tangible book value per share as of June 30, 2025, after giving effect to this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.26</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Dilution per share to new investors purchasing shares in this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.79</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
foregoing discussion and table illustrates the dilution in net tangible book value per share to the holders of the Warrants as of June
30, 2025. The foregoing table illustrates this calculation on a per share basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above discussion and table
are based on 52,426,282 shares of our common stock issued and outstanding as of June 30, 2025, except as described, and excludes, as of
such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Approximately 1,077,000&nbsp;shares of common stock issuable upon the vesting of outstanding restricted stock units;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Approximately 2,397,000 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $2.03 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 491,000 shares issuable upon the exercise of outstanding stock options granted outside of our Equity Incentive Plans at a weighted average exercise price of $1.53 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Approximately 1,692,000 shares reserved for future issuances under the 2021 Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Approximately 278,000 shares reserved for future issuances under the Consultant Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">425,109 shares of our common stock issuable upon exercise of underwriter warrants issued to Public Ventures&nbsp;in connection with an underwritten public offering at an exercise price of $1.1375 per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">15,147,606 shares of common stock issuable upon exercise of certain redeemable warrants outstanding at an exercise of $1.05 per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; background-color: white">2,795,395&nbsp;</FONT><FONT STYLE="font-size: 10pt">shares of common stock issuable upon exercise of certain pre-funded warrants outstanding at an exercise of $0.0001 per share; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">432,432 shares of common stock issuable upon exercise of placement agent warrants issued to Public Ventures as placement agent at an exercise of $1.1375 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion and table above
assume no exercise of any other outstanding warrants. To the extent that other outstanding warrants are exercised, you may experience
further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if
we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through
the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>DESCRIPTION OF SECURITIES BEING REGISTERED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the issuance
of 5,267,222 shares of common stock upon the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary of certain
material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities. You should
refer to our bylaws, as amended from time to time, and our certificate of incorporation, as amended from time to time. The summary below
is also qualified by reference to the provisions of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;), as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized and Outstanding Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation
authorized capital stock consists of 89,500,000 shares, $0.0001 par value per share, consisting of: (i)&nbsp;87,500,000 shares of common
stock; and (ii)&nbsp;2,000,000&nbsp;shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 20, 2025, we
have (i)&nbsp;52,426,282 shares of common stock issued and outstanding, and (ii)&nbsp;0 shares of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dividend Rights</I>. The
DGCL permits a corporation to declare and pay dividends out of &ldquo;surplus&rdquo; or, if there is no &ldquo;surplus,&rdquo; out of
its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. &ldquo;Surplus&rdquo; is defined
as the excess of the net assets of the corporation over the amount determined to be the capital of the corporation by the board of directors.
The capital of the corporation is typically calculated to be (and cannot be less than) the aggregate par value of all issued shares of
capital stock. Net assets equals the fair value of the total assets minus total liabilities. The DGCL also provides that dividends may
not be paid out of net profits if, after the payment of the dividend, capital is less than the capital represented by the outstanding
stock of all classes having a preference upon the distribution of assets. Delaware common law also imposes a solvency requirement in connection
with the payment of dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable law
and the rights and preferences of any holders of any outstanding series of preferred stock, the holders of common stock will be entitled
to the payment of dividends on the common stock when, as and if declared by the board of directors in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting Rights</I>. Holders
of common stock will be entitled to one vote for each share held as of the record date for determining stockholders entitled to vote on
such matters, except as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Right to Receive Liquidation
Distributions</I>. Subject to the rights and preferences of any holders of any shares of any outstanding series of preferred stock, in
the event of any liquidation, dissolution or winding up of the Company, the funds and assets of the Company that may be legally distributed
to the stockholders will be distributed among the holders of the then outstanding common stock pro rata in accordance with the number
of shares of common stock held by each such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Matters</I>. All
outstanding shares of the common stock will be fully paid and nonassessable. The common stock will not be entitled to preemptive rights
and will not be subject to redemption or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
certificate of incorporation provides that shares of preferred stock may be issued from time to time in one or more series. The board
of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional
or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board
of directors will be able to, without stockholder approval, issue preferred stock with voting and other rights that could have anti-takeover&nbsp;effects.
The ability of the board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring
or preventing a change of control of us or the removal of existing management. We have no preferred stock outstanding at the date hereof.
Although we do not currently intend to issue any shares of preferred stock, we cannot assure you that we will not do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April&nbsp;23, 2024, we completed an underwritten public offering, whereby we sold 4,620,760 shares of common stock and accompanying Warrants
to purchase up to 4,620,760 shares of common stock, which included a 45-day option for Public Ventures, as underwriter of the public offering,
to purchase up to an additional 693,114 shares of common stock and Warrants to purchase up to 693,114 shares of common stock, or up to
693,114 shares of common stock only, at a price of $0.92 per set of one share of common stock and one Warrant. Subsequently, on May&nbsp;15,
2024, Public Ventures exercised its over-allotment option in full to purchase an additional 693,114 shares of common stock and Warrants
to purchase up to 693,114 shares of common stock. As of the date hereof, 46,652 Warrants have been exercised and the shares of common
stock underlying such exercised Warrants have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Exercise Price</I>. The
initial exercise price of the Warrants is $1.05&nbsp;per share of common stock. The exercise price is subject to appropriate adjustment
in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting
our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Exercisability</I>. The
Warrants are exercisable at any time after the date of issuance, in whole or in part, and at any time up to the date that is five years
from the date of issuance, at which time any unexercised Warrants will expire and cease to be exercisable. The Warrants will be exercisable,
at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full in immediately
available funds for the number of shares of common stock purchased upon such exercise. No fractional shares of common stock will be issued
in connection with the exercise of a Warrant. In lieu of fractional shares upon exercise of a Warrant, we will, at our election, either
pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the exercise price or round up to
the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Transferability</I>. A
Warrant in book entry form may be transferred at the option of the holder through the facilities of The Depository Trust Company (&ldquo;DTC&rdquo;)
and Warrants in physical form may be transferred upon surrender of the Warrant to the warrant agent together with the appropriate instruments
of transfer. Pursuant to a warrant agent agreement between us and the warrant agent, the Warrants were issued in book-entry form and were
represented by one or more global certificates deposited with DTC and registered in the name of Cede&nbsp;&amp; Co., a nominee of DTC,
or as otherwise directed by DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Redemption.</I>&nbsp;At
any&nbsp;time prior to the full exercise or the termination date of the Warrants, the Company has the right to call the Warrants for redemption
upon 30 days&rsquo; prior written or published notice at a price of $0.01 per Warrant, provided that the closing price of the common stock
reported, for at least 20 of the 30 consecutive business days ending on the business day prior to the Company&rsquo;s giving notice of
redemption, has been at least $2.275&nbsp;per share, subject to adjustment. Holders of the Warrants have the right to exercise the Warrants
prior to the date set forth in the Company&rsquo;s notice of redemption. After such date, all rights of the holders will terminate, other
than the right to receive the redemption price of $0.01 per Warrant, without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Fundamental Transactions</I>.
In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or
reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets,
or our consolidation or merger with or into another person, the holders of the Warrants will be entitled to receive upon exercise of the
Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants
immediately prior to such fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Exchange Listing</I>. The
Warrants are not listed on Nasdaq or any other national securities exchange or any other nationally recognized trading system, and we
do not intend to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Rights as a Stockholder</I>.
Except as otherwise provided in the Warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holder of
a Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises
the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The transfer agent and registrar for our common
stock is VStock Transfer, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Trading Symbols and Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common stock is listed on Nasdaq under the
symbol &ldquo;CLIR.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock referenced
on the cover page&nbsp;of this prospectus will be offered solely by us and will be issued and sold upon the exercise of the Warrants described
herein. The shares of common stock issuable upon exercise of the Warrants were previously registered pursuant to our previous &ldquo;shelf&rdquo;
registration statement on Form&nbsp;S-3 (File No.&nbsp;333-265967).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
issuable upon the exercise of the Warrants will not be offered through underwriters, or brokers or dealers. We will not pay any compensation
in connection with the offering of the shares of common stock upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the shares
of common stock offered hereby will be passed upon for us by Mitchell Silberberg&nbsp;&amp; Knupp LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements for ClearSign Technologies Corporation as of December&nbsp;31, 2024 and 2023, and for each of the two years in the period ended
December&nbsp;31, 2024, incorporated in this prospectus by reference to the&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000155837025004155/clir-20241231x10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2024</A> have been so incorporated in reliance on the report of BPM CPA LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>INFORMATION INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to incorporate
by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring
you to those documents. The information incorporated by reference is considered to be part of this prospectus. Because we are incorporating
by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some
of the information included or incorporated in this prospectus. Specifically, we incorporate by reference the documents and information
filed with the SEC (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with
SEC rules) listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our Annual Report on&nbsp;Form&nbsp;10-K&nbsp;for the fiscal year ended December&nbsp;31, 2024, filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000155837025004155/clir-20241231x10k.htm" STYLE="-sec-extract: exhibit">March&nbsp;31, 2025</A>, as amended by our Annual Report on&nbsp;Form&nbsp;10-K/A&nbsp;for the fiscal year ended December&nbsp;31, 2024, filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925053646/tm2516383d1_10ka.htm" STYLE="-sec-extract: exhibit">May&nbsp;28, 2025</A>;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our Quarterly Reports on Form&nbsp;10-Q&nbsp;for the fiscal quarter ended March&nbsp;31, 2025, and June 30, 2025, filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000155837025007875/clir-20250331x10q.htm" STYLE="-sec-extract: exhibit">May&nbsp;15, 2025</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000155837025011555/clir-20250630x10q.htm" STYLE="-sec-extract: exhibit">August 14, 2025</A>, respectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our Current Reports on Form&nbsp;8-K&nbsp;filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925031996/tm2511519d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;4, 2025</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925052251/tm2516021d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;23, 2025</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925052998/tm2516138d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;27, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925067452/tm2520697d1_8k.htm" STYLE="-sec-extract: exhibit">July&nbsp;11, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925068797/tm2521146d1_8k.htm" STYLE="-sec-extract: exhibit">July&nbsp;18, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925071166/tm2521893d1_8k.htm" STYLE="-sec-extract: exhibit">July&nbsp;28, 2025</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925075708/tm2522983d1_8k.htm" STYLE="-sec-extract: exhibit">August&nbsp;8, 2025</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1434524/000110465925079277/tm2523643d1_8k.htm" STYLE="-sec-extract: exhibit">August 15, 2025</A>; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the description of our common stock contained in <A HREF="https://www.sec.gov/Archives/edgar/data/1434524/000155837025004155/clir-20241231xex4d1.htm" STYLE="-sec-extract: exhibit">Exhibit&nbsp;4.1</A> to our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2024,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1434524/000155837025004155/clir-20241231xex4d1.htm" STYLE="-sec-extract: exhibit">filed with the SEC on March&nbsp;31, 2025</A>, and any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, all documents
subsequently filed by us pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (not including any information furnished
under Item 2.02, 7.01, or 9.01 of Form 8-K or any other information that is identified as &ldquo;furnished&rdquo; rather than filed, which
information is not incorporated by reference herein) after the date of the initial registration statement of which this prospectus is
a part and prior to the effectiveness of the registration statement, as well as subsequent to the effectiveness of such registration statement
and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters
all securities then remaining unsold, shall be deemed to be incorporated by reference in the registration statement, of which this prospectus
forms a part, and to be a part hereof from the date of filing of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of
the registration statement, of which this prospectus forms a part, to the extent that a statement contained herein, or in any other subsequently
filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the registration statement, of which this
prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon written or oral request,
we will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge, a copy of any or all
of the documents incorporated by reference, other than exhibits to those documents unless the exhibits are specifically incorporated by
reference in the documents. Please send requests to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ClearSign Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8023 E. 63<SUP>rd</SUP>&nbsp;Place, Suite&nbsp;101</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tulsa, OK 74133<BR>
<FONT STYLE="background-color: white">(918) 236-6461</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have filed with the SEC, under the Securities Act, a registration statement on Form&nbsp;S-1 relating to the securities offered hereby.
This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto.
For further information with respect to our company and the securities we are offering by this prospectus you should refer to the registration
statement, including the exhibits and schedules thereto. The SEC also maintains an Internet site that contains reports, proxy and information
statements and other information regarding registrants that file electronically with the SEC. The SEC&rsquo;s website address is http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and periodic reporting requirements of the Exchange Act and, in accordance therewith, we file periodic reports, proxy statements and other
information with the SEC. Such periodic reports, proxy statements and other information are available for inspection and copying at the
website of the SEC referred to above. We maintain a website at www.clearsign.com. You may access our Annual Reports on Form&nbsp;10-K,
Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K and amendments to those reports filed pursuant to Sections 13(a)&nbsp;or
15(d)&nbsp;of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. Our website and the information contained on that site, or connected to that site, are not incorporated
into and are not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2523685d3_424b4img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,267,222 Shares of Common Stock Underlying
the Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>August 21, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2523685d3_424b4img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2523685d3_424b4img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% 1\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^FDXI3UJ
MO=3I;PM([  "IE)15P'M.J, [ 9X&:<&R2*\[U'6+B]O/.C<JB'Y175Z#JRZ
MA;C?@2J,&N:&(4I6)N;@I:8#3\UU%!1FDS29H =FC--!XHW 4P'9HIN\4N[F
M@!:**,T %%%% !1110 449HS0 4444 &<49IK,,XIN^@"3-&:;O%)O% 7'&D
MII<#DG H21)%W(P8>HH DHI.:6@ HHHH ***,T %%%% #6..]<%XIUMKBZ^P
MV[$C.#CN:Z;Q+J:Z7I,LQ;:Y&%^M<=X-TTW]T^I7>2@)*YZ5$X<RL!M:1X;3
M[!F[7,D@X'I7/W#7/AW5\EB%+=>V*OZYXW%IJB0V>&CC/[P^U:NI0VOBC0A<
M6^&DVY'_ ->LOJW+J0T;VG7B7MFD\;95A^M6\\5Y[X&U5H[R72YF.5R &/?V
MKMM2O$T^PFN7/$:D_C6Z3LD-,I:YXCLM$AS.P:0]%K@KWXDZC+(1:01HF>"1
MDUS\GVSQ/KN'9G>5\#'\*UZCI'@W2],@4/"LTN.2_-;^['<9Q-O\1=6@96N8
M5=,\C&#^%=SX?\766N+@?NYO[C&I=1\+Z5?Q%'M4#'^)!C%<YHW@![+6?M,U
MP?*1LQA:EN#6@(U/&/B>Y\/QQ&")7+GG-:_AS4Y=5T>&\F4*S]A7%_% 8CLP
M,X'ZUTW@C_D5K:AKW;A<Z3-&>:P-?\36FA0DRD-,?NQBN(D\>ZY=,7L[7;'V
M^3-3&%T%SU;-+7FND_$647"P:E %SP7 P17H5M<1W-NDT+;HV&12<;!<G)Q1
MFL#Q%XHM-"B^?$DQZ(#7"R_$+69W9K:!50'IMSFFHL39ZSTI-U>;V'Q'E:&1
M+Z ).%^7MDUJ^$O%ESK]W+#/$JJ@X(H<+:C3.SW'OQ0&STKB/%/B^YT+5DMH
MXU:-E!)/6L:X^(&I7%RBV%N/+R 3MZT<N@7/1-0OK;3;22ZN9/+BC&68UXYX
M@^-LK7#V^AV8;!P)",YK3^,=Y>#PE8*7*"4YEV_3I7._!O3]"GDN);X1/=J?
MW22^E5&*M=DWN4/^%L>,XB)7ME,?_7+%=9X9^-,%Y.EIJ]KY$C$#S%Z UZA)
MI>F7,)C-I;NAXQM%<7)\)-!;Q$NIJA6)3N, X4FB\16-_P 6:I+!X:DN+,%O
M-'##T]:R/AMJ5W<V<\,^YD5LJS5I>--4_P"$>\)RW45NC^6 !&PXP.U8GPN\
M5OXFM+IGLH+7RV'$8ZTK7B.^IZ-S1FN.\9^/;'PC;8<B6[8?+$#7E,_QD\4W
M<Q:RM$$>> (\U*CH-O4^A]U)YBUXAIGQKN#83Q:C9B.\090XP&KJ?AKX[O?&
M!O?ML")Y7*@4^5H7-K8]&+&@/FO&M4^+5]IWBR;39;>/[+%)M9N^*RM8^,^K
MS7CIHUD!;H<!RN[-/V8G.Q[WNIP->'>%/C/<3WD=IKD"#>V!(O&/K7M,$RSP
MK+$P9' 8-ZU+BT4I7.$^([R7%SI^G(3^^<<#ZU8\07Z>&?#$=E;X6:1,<=:L
M^);0R>*M(N&&8U?&<=*X[Q[=F?Q"83G;&,"KBN;0&<ON>3+$Y)&6KK? VNG3
M]2-C*W^C3$ 9/0UQ^3@@=*>DIADCE!Y1@175*/NV,U)W.ZUZT.C>-+.\AXBG
MD&<<5U'C9BWA6=D)&X#-8VM1MJ=IH;+_ *PR*3]*ZW5M/%]HDEIU)CXS7*W9
MHTZ'G7PW1&UJ5V^9@G%>K@?2O#=)O9_#?B%F="NQML@/I7L.G:O::G LMM.C
M9'*D\BBHK@F:87%!'%5;B^@M(3+-,JJ!GDUS^G>.-/U#4&LURISA6/1JS<78
M=S ^*'^KM/J?Y5T7@]Q#X1AD/14)KGOB>I-O;'KS6SX.>.Z\)K CC<%*L.XK
M;_EV)GG5_>#5O$QEO9"(/,(;GHHKT&R\2^%K*W2"*2, #G*\UYTUI#!XC>UO
M@1$93D^@]:[^#X?:)<1++'([(XR"&I6LD(P/%]QX?U. 3V,J+<#J%&,U?^'V
MM2BSNK65BPB4NN3VJQ?>"_#NFQB2[G= 3@?-UK3T?PUI5K#//IDA?S(ROWO6
MBZ \]_?^*/%91FW*\AX/917K>GZ'86-H(8K>/ '4J.37DFD3_P!A^+,SC;LE
M*'Z&O:()X[B%9(F#(W(VTI/L!QOC/PM:SZ=)?6\02:+EMO Q6-\,AG5+K'3:
M*ZOQCK$%AH<\3.IEE4J%!KE/AESJ5R?1!FFFW#495^(P#>(X1ZH!^M=YH&CV
M,&CVI%M&6*ABQ4=:X3XB'_BI(?\ ='\Z],T?C1K4?],Q4MZ!U,WQ9X8MO%.C
M/8SG9_<?^Z:\%U#X8^*M"NF:T$DR(?EDB.#BO?O$GB?3_#%@;J^D Z[8^[53
M\->-M(\2VJR6\Z1S-UB<\BE!M ['@2:CXZT=L-)?*!_>!(K<\/?&'6K"\6'5
MU6XAW88[<,*]_F^S&-C*(2N.2^*^;?BFVDOXH8:2J !<2>7T+5K&5^A)ZQ\1
M=0AU/X:27EN=T<RAE]JY?X&2B'3-5E_NG/Z5+=P30? U%N%(<C< ?2H_@:@G
MT?58U_B./THMHR>IPE\;GQI\19(968B2<H#_ '54XXKZ'T7PKI6B6,=O;V<)
M*@;F90237SK%-)X3^)#R7(95BNF)SZ$YKZ8T[5K/4K2.YM9T='&3ANE1).VA
M74\V^*W@>QET=]7LH%AGA^9]HP"/I63\"#N.IGZ=?I73?%?Q3967AR73Q*K7
M,XQM4Y.*YKX$Y!U($Y.!_*JUY=27;F.(\267]I?$>YLLX$MSM./2OH31_".C
MZ7IT5M'80G:@W,R@DG%>"WQS\7V_Z^OZU]-* 40D#H*4WH4E>1\^_&'PQ8Z'
M>VM]81"$3<LHZ9KU'X9ZC-J'A&S\XY,<87)[UQOQYXM--';)KIOA)_R*<6?0
M42^$%N=O>V<=VJ*_5"&!^E>;>/M!G6^%_"C.A'S8[5ZH0>U120I*A1U#*1@@
MCK41ERLMH^=CA2>?PJ_I6E7&K7T4,4996(R<=*]8N_ VC74XE,&PYSA>!6OI
M^CV>FQE+6%4SU('-:SJW6AFEJ06>DQ0BVW@$PI@?6M4@8H"XXIQ7(K%NYJ<A
MXF\'0:TIFMP([H?Q>M<!)X<\1:5*?+67 Z&,D5[9M'?FC:".0#3YA61XD-'\
M2:DP21+E@3R9&.*[+PSX$2PG2\U B29>44=!7=[0.@Q0!0YZ6%8QO$&A0:[I
MYMY/E8?</H:XC0O#FNZ/X@2$2,MMU+CH:]0*@_6DV?A]*2E=6%8X_P 5^#TU
ME?M-L0EV!S_M5Q\*>*]&!MXQ*R]N^*]AV\]:0Q@^F?7%/F"QY'!X;\1>(9PV
MH,ZQ9_CKTK1M'M]'L%MX<DCJ3W-:@%*.U)NY5CAO%W@L:HYNK,;;C.2!WKCX
M8/%6E?Z/ )U3/ !R*]G*\TWRQW&<478K'DD/A'6]526[ORY<#*HQZUL^ M$U
M#3+^YDNX3&K 8]Z]$V^]!7G/ITJN?2Q2/-O&VA:CJ6N0SVMN708!(KO=+B>'
M3+:*08=8QD>AJWBG8XJ L<IXT\%67B[3Q%<$K,O,;YZ&O#M3^&7BK0+AI+17
ME13\KPL0<?A7TT5I2H]*J,K$N-SY:^P^.[P"!DOV'3!8UUG@_P"#U_-=1WFO
M-L16W>7G);ZU[NL2@< ?E2E>, D5;J=B5&QQGCW1I[SP5+INF0;G "HB^@KG
M?@WX=U70+.[74K8PL[9 KU4KSUI-OIQ4J>EBFD>>_$#X<6_BI?MMN5@O@N-Q
MZ-]:\KC\#>/=)<V]F9ECZ?(YP:]%^*]]XILXHFTE6%D,&1XQ\V:Y/3?C;JEC
M9K;WVGB:5!@.>#^-7%NPFC/NOAY?Z;H=UK'B*Z)N /W:,V3^M;_P%A?R=3F(
M^5FP#7)ZQXA\3?$F\CLX+=HX6.-B [<>]>Y> _"D?A3P]'9X_?-\TGUIREH9
MN-WH>57G@K7I/B8VHK9G[+]HW[_:O>TW!5![**DV^U&W/_UJR;ON:15CROXP
M^']4UZVL1IML9FC/S"M_X:Z5?:3X?2VOH?*D Z5VOEC-*%Q1?2P["T445F4(
M:***:$MQ1UI:**0QIZTHHHJP$- HHI +1BBB@04444 %%%%,H****0F':BBB
M@$%%%% !1VHHH *2BBD,*,444R602QHZ,LBAU/&&&16'<>#/#US-YDNEP,Q/
G7;1151$:6GZ/I^EJ5LK2*'_=6KZ #-%%#"))BDHHJ1BT444#/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
